Observing Real-World Outcomes of Siltartoxatug Injection for Tetanus Prevention After Injury in a Large Patient Group

What this Trial Is About

Researchers are observing patients who receive Siltartoxatug Injection, also known as Sintetol4, to prevent tetanus following injury. This large-sample, real-world registry aims to document injury and wound conditions and evaluate clinical outcomes related to tetanus prevention. The study focuses on collecting safety information and any adverse reactions after receiving the injection. Participants in this observational study receive Siltartoxatug Injection as part of their tetanus prophylaxis after injury. The study does not involve randomization or comparison groups but follows patients over time to monitor outcomes. A key part of the study is the follow-up at 90 days after administration to assess whether tetanus develops and to record any safety events. During the study, patient injury details and wound conditions will be carefully noted. Safety data will be selectively collected to identify any adverse reactions or serious events linked to Siltartoxatug use. The main outcome measure is the occurrence of tetanus within 90 days post-injection. Participants are followed for this 90-day period to evaluate treatment outcomes and safety.

A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury